[Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
OBJECTIVE
To reveal prognostically significant factors affecting efficacy of glivek therapy in untreated (duration of the disease < or = 6 months) and pretreated (duration of the disease > 6 months) patients with chronic myeloid leukemia (CML) in a chronic phase.


METHODS
A total of 338 patients (64 untreated and 274 pretreated) with a chronic-phase CML on glivek therapy entered the trial.


RESULTS
Five-year survival on glivek was high (89, 98 and 88% in untreated and pretreated patients, respectively). Incidence of transformation in the acceleration phase and blast crisis was low both in untreated and pretreated patients (1.6 and 11%, respectively) and correlated with the rate of a complete cytogenetic response (CCR). Untreated patients had no factors affecting treatment efficacy negatively, CCR probability was 96%. Blastemia, thrombocytosis and splenomegaly reduced CCR probability significantly in pretreated patients. Slow reduction of the tumor mass, late achievement of a complete hematological response and a cytogenetic response decreased probability of CCR.


CONCLUSIONS
Glivek is a drug of choice for patients with chronic-phase CML. High probability of CCR both in untreated and pretreated patients lowers the risk of the disease transformation into the phase of acceleration/blast crisis and raises overall survival in both groups.
Zaritskiĭ
A Iu
AIu
Lomaia
E G
EG
Vinogradova
O Iu
OIu
Druzhkova
G A
GA
Kolosheĭnova
T I
TI
Loria
S S
SS
Pospelova
T I
TI
Krylova
I V
IV
Kruglov
S S
SS
Kuznetsov
S V
SV
Chelysheva
E Iu
EIu
Abakumov
E M
EM
Sokolova
M A
MA
Nemchenko
I S
IS
Zakharova
E S
ES
Goriacheva
S R
SR
Kolosova
L Iu
LIu
Vakhrusheva
M V
MV
Liamkina
A S
AS
Chernova
O A
OA
Machiulaĭtene
E R
ER
Ivanova
V L
VL
Udal'eva
V Iu
VIu
Shneĭder
T V
TV
Ogorodnikova
Iu S
IuS
Zhuravlev
V S
VS
Zakharova
A V
AV
Martynkevich
I S
IS
Domracheva
E V
EV
Afanas'ev
B V
BV
Abdulkadyrov
K M
KM
Kovaleva
L G
LG
Khoroshko
N D
ND
Turkina
A G
AG
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001752:Blast Crisis / Q000453:epidemiology / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D015994:Incidence; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D012307:Risk Factors; D012426:Russia / Q000453:epidemiology; D015996:Survival Rate / Q000639:trends; D013997:Time Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases